相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy
Beatriz Sanchez-Correa et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma
Cedric Rossi et al.
ONCOIMMUNOLOGY (2019)
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
Frank Vari et al.
BLOOD (2018)
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Joy Hsu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
Bruce D. Cheson et al.
ANNALS OF HEMATOLOGY (2017)
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
R. Marcus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions
Simone Battella et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2016)
Breakthrough therapies in B-cell non-Hodgkin lymphoma
C. Y. Cheah et al.
ANNALS OF ONCOLOGY (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes
Lauren R. Teras et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
Laurie H. Sehn et al.
LANCET ONCOLOGY (2016)
Low natural killer (NK) cell counts in peripheral blood adversely affect clinical outcome of patients with follicular lymphoma
L. He et al.
BLOOD CANCER JOURNAL (2016)
Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas
Marie Tosolini et al.
ONCOIMMUNOLOGY (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Obinutuzumab in hematologic malignancies: Lessons learned to date
Tim Illidge et al.
CANCER TREATMENT REVIEWS (2015)
Improving natural killer cell cancer immunotherapy
Melissa M. Berrien-Elliott et al.
CURRENT OPINION IN ORGAN TRANSPLANTATION (2015)
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles et al.
NATURE MEDICINE (2015)
Robust enumeration of cell subsets from tissue expression profiles
Aaron M. Newman et al.
NATURE METHODS (2015)
Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies
Minh Ngoc Duong et al.
MABS (2015)
Building better monoclonal antibody-based therapeutics
George J. Weiner
NATURE REVIEWS CANCER (2015)
Cell Growth in Aggregates Determines Gene Expression, Proliferation, Survival, Chemoresistance, and Sensitivity to Immune Effectors in Follicular Lymphoma
Pauline Gravelle et al.
AMERICAN JOURNAL OF PATHOLOGY (2014)
Whole-genome integrative analysis reveals expression signatures predicting transformation in follicular lymphoma
Marianne Brodtkorb et al.
BLOOD (2014)
EZH2 Mutations in Follicular Lymphoma from Different Ethnic Groups and Associated Gene Expression Alterations
Shuangping Guo et al.
CLINICAL CANCER RESEARCH (2014)
Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation signaling in human TCRVγ9+ γδ T lymphocytes
Emilie Decaup et al.
IMMUNOLOGY LETTERS (2014)
The yin and the yang of follicular lymphoma cell niches: Role of microenvironment heterogeneity and plasticity
Patricia Ame-Thomas et al.
SEMINARS IN CANCER BIOLOGY (2014)
Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma
Michael R. Green et al.
BLOOD (2013)
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)
John Radford et al.
BLOOD (2013)
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Sylvia Herter et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Low NK cell counts in peripheral blood are associated with inferior overall survival in patients with follicular lymphoma
Danielle Shafer et al.
LEUKEMIA RESEARCH (2013)
An Integrated Genomic and Expression Analysis of 7q Deletion in Splenic Marginal Zone Lymphoma
A. James Watkins et al.
PLOS ONE (2012)
Innate predisposition to immune escape in follicular lymphoma cells
Pauline Gravelle et al.
ONCOIMMUNOLOGY (2012)
Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
Waleed Alduaij et al.
BLOOD (2011)
The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
Elias Campo et al.
BLOOD (2011)
γδ T-cell killing of primary follicular lymphoma cells is dramatically potentiated by GA101, a type II glycoengineered anti-CD20 monoclonal antibody
Mounia Sabrina Braza et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101
Stephane Dalle et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Rituximab inhibits B-cell receptor signaling
Samar Kheirallah et al.
BLOOD (2010)
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
PKC zeta-mTOR pathway: a new target for rituximab therapy in follicular lymphoma
Ludivine Leseux et al.
BLOOD (2008)
Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas
Deepti Behl et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Syk-dependent mTOR activation in follicular lymphoma cells
Ludivine Leseux et al.
BLOOD (2006)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
Gene Expression Omnibus: NCBI gene expression and hybridization array data repository
R Edgar et al.
NUCLEIC ACIDS RESEARCH (2002)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
分享论文
